Welcome to our dedicated page for Cardlytics news (Ticker: CDLX), a resource for investors and traders seeking the latest updates and insights on Cardlytics stock.
Cardlytics (CDLX) delivers purchase-based advertising intelligence through partnerships with financial institutions, transforming consumer spending data into actionable marketing insights. This news hub provides investors and analysts with essential updates on the company’s evolving strategies in digital advertising and data analytics.
Access real-time announcements including quarterly earnings, product launches, and partnership expansions. Our curated collection features press releases about platform innovations, client acquisitions, and industry recognition – all critical developments for understanding CDLX’s market position.
Key updates cover operational milestones across both core platforms: the proprietary bank advertising channel and Bridg cloud-based analytics solutions. Track developments in campaign measurement capabilities, financial institution collaborations, and data security enhancements that shape the company’s competitive edge.
Bookmark this page for streamlined monitoring of CDLX’s financial performance and strategic initiatives. Combine our news feed with SEC filings and earnings call transcripts available through Stock Titan’s financial research tools for comprehensive analysis.
Cardlytics (NASDAQ: CDLX) has announced the granting of 124,050 restricted stock units to 11 newly hired employees as employment inducements, approved by the Compensation Committee of Cardlytics' Board of Directors on April 24, 2025.
The grants, issued under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), feature a structured vesting schedule: 50% of the units will vest on the first anniversary of the grant date, with the remaining 50% vesting quarterly over the subsequent 12 months. Vesting is contingent upon continuous employment with Cardlytics.
Cardlytics (NASDAQ: CDLX) has scheduled the release of its first quarter 2025 financial results for May 7, 2025, after market close. The company will host a conference call on the same day at 5:00 pm Eastern time (2:00 pm Pacific time).
Investors can access the live audio webcast through the Cardlytics Investor Relations website at ir.cardlytics.com or by registering through the provided link. A replay will be available on the website following the call. For those preferring to dial in, the conference call can be accessed at +1 800-549-8228 using Conference ID: 86123.
Cardlytics (NASDAQ: CDLX) reported challenging fourth quarter and full year 2024 results, with significant revenue declines. Q4 revenue fell 17.0% to $74.0 million, while full-year revenue decreased 10.0% to $278.3 million.
The company posted a Q4 net loss of $(15.6) million, or $(0.31) per share, an improvement from the $(100.8) million loss in Q4 2023. The full-year 2024 net loss widened to $(189.3) million, or $(3.91) per share.
Key metrics showed mixed results with Cardlytics MAUs slightly decreasing to 167.3 million in Q4 2024, down 0.4% year-over-year, while full-year MAUs increased 3.0% to 166.9 million. ARPU declined 16.7% to $0.44 in Q4 and dropped 12.6% to $1.67 for the full year.
Management remains focused on delivering sequential improvements and positive Adjusted EBITDA in 2025, while investing in platform modernization and expanding partner networks.
Cardlytics (NASDAQ: CDLX) has announced the granting of 225,800 restricted stock units to 18 newly hired employees as employment inducements. The grants, approved by the Compensation Committee of Cardlytics' Board of Directors on February 26, 2025, comply with Nasdaq Listing Rule 5635(c)(4) and were issued under the company's 2022 Inducement Plan.
The vesting schedule stipulates that 50% of the restricted stock units will vest on the first anniversary of the grant date, with the remaining 50% vesting quarterly over the subsequent 12 months, contingent upon continuous employment with Cardlytics.
Cardlytics (NASDAQ: CDLX) has scheduled the release of its fourth quarter and full year 2024 financial results for March 12, 2025, after market close. The company will host a conference call on the same day at 5:00 pm Eastern time (2:00 pm Pacific time).
Investors can access the live audio webcast through the Cardlytics Investor Relations website or by registering through the provided link. A replay will be available on the website following the call. For those preferring to dial in, the conference call can be accessed at (+1) 800-549-8228 using Conference ID: 91460.
Cardlytics (NASDAQ: CDLX) reported Q3 2024 financial results showing revenue of $67.1 million, down 15% year-over-year. The company posted a net loss of $(145.2) million, or $(2.90) per share, compared to a net loss of $(24.0) million in Q3 2023. Monthly Active Users increased 2% to 166.4 million, while ARPU decreased to $0.40 from $0.49. Adjusted EBITDA was a loss of $(1.8) million versus a gain of $3.9 million last year. For Q4 2024, the company expects revenue between $62.0-$67.0 million, representing a 30-25% year-over-year decline.
Cardlytics (NASDAQ: CDLX), a digital advertising platform operating through banking channels, has scheduled its Q3 2024 earnings release for November 6, 2024, after market close. The company will host a conference call at 5:00 PM ET to discuss the financial results. Investors can participate via audio webcast or dial-in, with a replay available on the company's investor relations website.
The Schall Law Firm, a national shareholder rights litigation firm, is investigating Cardlytics, Inc. (NASDAQ:CDLX) for potential securities law violations. The investigation centers on whether Cardlytics issued false or misleading statements or failed to disclose important information to investors. The company's Q2 2024 financial results, released on August 7, 2024, significantly missed projections made just three months earlier. Cardlytics attributed the shortfall to "fast-paced changes to our technology platform," but when questioned by analysts, management admitted that these technology issues had been known for "a quarter or two." The firm encourages affected shareholders to participate in the investigation and offers free consultations to discuss investor rights.
Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks' digital channels, has announced the granting of 49,900 restricted stock units to seven newly hired employees. The grants were approved by the Compensation Committee of Cardlytics' Board of Directors on August 19, 2024, as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
The restricted stock units were granted under the Cardlytics, Inc. 2022 Inducement Plan. For all recipients, 50% of the units will vest on the first anniversary of the grant date, with the remaining 50% vesting quarterly over the subsequent 12 months, subject to continuous service with Cardlytics.
Cardlytics (NASDAQ: CDLX) reported Q2 2024 financial results, showing mixed performance. Revenue decreased 9% year-over-year to $69.6 million, while billings increased 1% to $110.4 million. The company faced challenges with slower-than-anticipated billings growth and higher consumer incentives. Net loss improved to $(4.3) million from $(23.5) million in Q2 2023. Adjusted EBITDA loss narrowed to $(2.3) million from $(4.1) million last year.
Key metrics showed Cardlytics MAUs increased 3% to 165.5 million, but ARPU declined to $0.42 from $0.48 in Q2 2023. The company remains confident in its long-term potential despite near-term challenges. For Q3 2024, Cardlytics expects billings between $100-$106 million and revenue between $56-$63 million.
